Investigating the Usage of Abiraterone in African American Men with Metastatic Prostate Cancer
The initiation of ADT with abiraterone was delayed by 3 months in African American men. This discrepancy warrants an investigation of system level barriers to the timely initiation of abiraterone in African American men given its known oncologic benefits.
Authors
- Laurence Belkoff (ORCID: https://orcid.org/0000-0003-2789-6815)
- Thomas J. Guzzo
- Serge Ginzburg (ORCID: https://orcid.org/0000-0002-7971-2056)
- Marieke Jones (ORCID: https://orcid.org/0000-0001-5045-6725)
- Robert G. Uzzo (ORCID: https://orcid.org/0000-0003-2398-6530)
- Thomas L. Jang (ORCID: https://orcid.org/0000-0001-5886-3835)
- Bruce L. Jacobs (ORCID: https://orcid.org/0000-0003-1358-0764)
- Jeffrey Tomaszewski (ORCID: https://orcid.org/0000-0001-8415-2535)
- Jayanthi Raman (ORCID: https://orcid.org/0000-0002-1320-6177)
- Mihir Shah
- Christine Ibilibor (ORCID: https://orcid.org/0000-0002-3432-7883)
- Adam C. Reese (ORCID: https://orcid.org/0000-0001-9587-9852)
- Keith J. Kowalczyk (ORCID: https://orcid.org/0000-0002-3081-6815)
- Marc C. Smaldone (ORCID: https://orcid.org/0000-0003-4160-0005)
- Andres Correa
- John Danella
- Daniel Y. Lee (ORCID: https://orcid.org/0000-0001-9106-9342)
- Jeffrey Walker
- Matthew R. Smith
Institutions
- Rutgers, The State University of New Jersey (US)
- Fox Chase Cancer Center (US)
- Main Line Health (US)
- University of Pittsburgh (US)
- Thomas Jefferson University Hospital (US)
- MedStar Georgetown University Hospital (US)
- Einstein Healthcare Network (US)
- Cooper University Health Care (US)
- University of Virginia (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- Penn State Milton S. Hershey Medical Center (US)
- Temple University (US)
- MedStar Health (US)
Publication Details
- Journal
- Journal of Racial and Ethnic Health Disparities
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1007/s40615-025-02533-3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00